Abstract: Provided are a federated graph clustering method based on distributed graph embedding, a device, and a readable storage medium.

Abstract: A compound containing a bis(azanylylidene) sulfonyl structure of formula (I) as a PKR agonist and/or USP9X inhibitor, which can be used for treating related diseases mediated and regulated by PKR and USP9X, wherein the related diseases comprise, but are not limited to: sickle-cell anemia, ?-thalassemia, hereditary non-spherocytic hemolytic anemia, hemolytic anemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, congenital anemia, anemia of chronic diseases, colorectal cancer, kidney cancer, pancreatic cancer, breast cancer, lung cancer, esophageal cancer, melanoma, lymphoma, glioblastoma, or multiple myeloma.

Abstract: An optical adjustment method of a color film layer, a display panel, and a mobile terminal are provided by the present application. The display panel includes a plurality of pixel units, each pixel unit is disposed in a hexagon, wherein the hexagon is divided into six triangles around a center the hexagon. One pixel structure includes six closely-arranged pixel units. One pixel unit is correspondingly disposed in one triangle. In a pixel unit and a corresponding triangle, the pixel unit includes three sub-pixels which are respectively disposed at three vertex corners of the triangle and have different colors.

Abstract: Certain aspects of the present disclosure provide a method for wireless communication by a user equipment (UE) generally including receiving signaling indicating a set of physical random access channel (PRACH) configurations, receiving,, a physical downlink control channel (PDCCH) order to trigger a PRACH transmission associated with an additional PCI different from a first PCI associated with a serving cell, transmitting a PRACH associated with the additional PCI based on one PRACH configuration of the set of PRACH configurations that is associated with the additional PCI, receiving an indication of a timing advance (TA) associated with the additional PCI, and applying the TA for an uplink transmission associated with the additional PCI.

Abstract: Certain aspects of the present disclosure relate to wireless communications, and more particularly, to techniques for xx. A method that may be performed by a user equipment (UE) includes receiving, from a network entity, a first transport block (TB) comprising one or more code blocks (CBs), transmitting, to the network entity, an indication of a preferred code block group (CBG) allocation scheme selected for re-transmission of at least one CB of the one or more CBs based, at least in part, on a decoding status for each of the one or more CBs, and receiving, from the network entity, the at least one CB re-transmitted in accordance with the preferred CBG allocation scheme.

Abstract: There is provided a phase shifter having a phase shift region and a peripheral region, and including a first substrate, a second substrate and a dielectric layer between such two substrates; the first substrate includes a first dielectric substrate, a first electrode and a first auxiliary structure; the second substrate includes a second dielectric substrate, a second electrode and a second auxiliary structure; the phase shift region includes overlapping regions; the first electrode and the second electrode are located in the phase shift region, and have orthographic projections, on the first dielectric substrate, overlapped at least partially in the overlapping regions; the first auxiliary structure is in the peripheral region and on a side, close to the dielectric layer, of the first dielectric substrate; the second auxiliary structure is in the peripheral region and on a side, close to the dielectric layer, of the second dielectric substrate.

Abstract: Provided are an anti-CLDN-18.2 antibody-drug conjugate that specifically binds to CLDN-18.2 and a composition comprising same. Also provided are a method for using the antibody-drug conjugate of the present invention and a use thereof.

Abstract: A method of evaluating an ability of a large language model (LLM) to generate an accurate hypothesis model (HM) of a linear programming word problem (LPWP) is provided. An attributed bipartite graph of the HM is transformed into an attributed bipartite graph of the ground truth model of the LPWP. The number of transformation steps required for the transformation effectively measures the ability of the LLM to generate an accurate HM. The use of attributed bipartite graphs provide invariance in the order to LPWP variables and constraints. Corresponding apparatus and systems are also provided.

Abstract: This disclosure provides systems, methods, and apparatus, including computer programs encoded on computer-readable media, for implementing signaling for indicating a scheduled full duplex (FD) uplink (UL) and downlink (DL) traffic scheduling combination for differentiation of FD traffic. In some aspects, a BS may transmit a downlink control information (DCI) message that includes an indication of the scheduled FD UL and DL traffic scheduling combination. The FD UL and DL traffic scheduling combination may identify scheduled UL and DL transmissions for FD mode operation. The UE may receive the DCI message and identify the scheduled FD UL and DL traffic scheduling combination. In some aspects, the BS may provide a DCI message to the UE that indicates whether a DL transmission is being scheduled that at least partially overlaps with a scheduled UL transmission. The UE may initiate a power save mode based on the received DCI message.

Abstract: Disclosed herein is an imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a TLR7 agonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as TLR7 agonist.

Abstract: The present disclosure provides a polylactic acid composition and a method of preparing the same. The polylactic acid composition comprises a polymeric material and a reaction product obtained by reacting a compound represented by formula (A) with a compound represented by formula (B), the polymeric material comprising polylactic acid, the compound represented by formula (A) being a trimeric phosphazene-based substance, and the compound represented by formula (B) being diamine. The polylactic acid composition is favorable in both flame retardancy and toughness.

Abstract: A carbazate-functional compound includes a plurality of groups having the following structure: [formula (I)] where X forms at least a portion of: a urethane linkage, an ester linkage, or an ether linkage. At least one R1 from the plurality of groups is free of a hydroxyl-functional group.

Abstract: The present disclosure provides a method for preparing concentrated high-protein yogurt before fermentation, belonging to the technical field of dairy product processing. The method for preparing the concentrated high-protein yogurt before fermentation in the present disclosure includes: enabling a high-protein base material with a decalcification rate of 21.8-44.2% to be subjected to heat treatment at pH of 6.6-6.8 and temperature of 80-95° C. for 10-30 min; after that, cooling to 40-45° C., adding 0.05-0.2% (w/w) of a starter, and carrying out high end-point pH fermentation at 40-45° C. until the pH drops to 4.8-5.0; and then, performing low-temperature after-ripening to obtain the high-protein yogurt. Compared with high-protein yogurt prepared by a whey discharge process after fermentation, the concentrated high-protein yogurt prepared according to the present disclosure has similar or better soft texture, delicate taste, water holding capacity and digestibility, and is higher in calcium content.

Abstract: The present disclosure provides a high-entropy rare earth-toughened tantalate ceramic. The ceramic is prepared by sintering Ta2O5 powder and x types of different RE2O3 powder, 4?x?9, and the molar ratio of the RE2O3 powders is 1. RE2O3 powder and Ta2O5 powder having the molar ratio of RE to Ta being 1:1 are weighed, a solvent is added for mixing, and ball milling is performed by a ball mill to obtain mixed powder M; the powder M is dried at a temperature of 650-850° C. for 1.5-2 h to obtain dried powder; the powder is sieved to obtain powder N, the powder N is placed in a mold for first pressing to obtain a rough blank, and the rough blank is then pressed for the second time to obtain a compact blank; the compact blank is sintered to obtain the high-entropy rare earth-toughened tantalate ceramic.

Abstract: Embodiments of the present disclosure provide a flexible sensor, including a flexible substrate; a plurality of ultrasonic detectors, on the flexible substrate; and a plurality of detection circuits, respectively corresponding to the ultrasonic detectors; wherein each of the detection circuits is between the flexible substrate and the corresponding ultrasonic detector, and configured to drive the ultrasonic detector to emit an ultrasonic wave, and detect a detection signal output by the ultrasonic detector after receiving the ultrasonic wave; each of the ultrasonic detectors includes: a first electrode coupled to the corresponding detection circuit, a second electrode on a side of the first electrode away from the flexible substrate, and a piezoelectric induction layer between the first electrode and the second electrode; a plurality of holes are provided in a region other than a region where the detection circuits are located.

Abstract: The present disclosure provides a cryo-electron microscopy image processing method and apparatus, a terminal, and a storage medium. The cryo-electron microscopy image processing method includes: obtaining a cryo-electron microscopy image; encoding the cryo-electron microscopy image into latent variables through an encoder; converting the latent variables into an atomic model structure through a decoder; correcting the atomic model structure using a loss function to obtain a corrected atomic model structure, where the loss function includes a bond length constraint loss function, a clash constraint loss function, and a spring constraint loss function; and converting, through a projector module, the corrected atomic model structure into a density map represented by Gaussian spheres, and projecting the density map to obtain a projection image.

Abstract: The present disclosure describes a structure that includes an electromagnetic interference (EMI) immunity layer and a doped epitaxial layer on the EMI immunity layer. The EMI immunity layer has a first resistivity and a first thickness. The doped epitaxial layer has a second resistivity and a second thickness. A sum of thicknesses is defined by a combination of the first thickness and the second thickness. A first ratio is the sum of the first thicknesses to the second thickness. A second ratio is the second resistivity to the first resistivity. A product of the first ratio and the second ratio is equal to or less than about 1.

Abstract: Compositions and methods for inhibiting corrosion of metal surfaces are disclosed herein. Also disclosed are methods of manufacturing the corrosion inhibitors compositions. The corrosion inhibitor compositions include a reaction product of maleated fatty imidazoline formed from a fatty acid, e.g., maleated tall oil fatty acid and/or a maleated soya acid, with one or more amines. The reaction product can be further reacted with one or more of acrylic acid or acetic acid to form derivatives of a maleated fatty imidazoline acrylate compound or a maleated fatty imidazoline acetate compound, respectively.

Abstract: This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that can comprise STING polypeptide, a nucleic acid encoding said STING polypeptide, a STING inhibitor, a STING activator, a STING agonist, a STING antagonist, a STING modulating molecule, or a combination thereof. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine. This disclosure is also directed to a method for treating or preventing a disease using the pharmaceutical composition. The disease can include infectious diseases caused by viruses or other pathogens, for example, influenza, rabies, or respiratory illnesses such as severe acute respiratory syndrome (SARS) caused by coronaviruses, such as MERS-CoV, SARS-CoV, and Coronavirus Disease 2019 (COVID-19) caused by the virus SARS-CoV-2 and its variants.

Abstract: A scanning apparatus (110), a medical image obtaining method, and a medical image obtaining system (100) are provided. The scanning apparatus (110) comprises a gantry, a controller, a C-shaped arm, a radiation source (112), and a detector (113). The radiation source (112) and the detector (113) are arranged at both ends of the C-shaped arm. The C-shaped arm is connected to the gantry. The controller is configured to control a motion of the gantry to drive the C-shaped arm to move so as to scan a target object.